FDA Adds Pulmonary Aspiration Warning to GLP-1 Label

The FDA has recently updated the labels for all glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications used for weight loss and diabetes management, with a new safety warning. This update, issued on November 5, 2024, addresses the risk of pulmonary aspiration during general anesthesia or deep sedation.

The affected medications include:

• Semaglutide (Ozempic, Rybelsus, Wegovy)
• Liraglutide (Saxenda, Victoza)
• Tirzepatide (Mounjaro, Zepbound)

New Warning Details

The updated label now includes a subsection under "Warnings and Precautions" that states:

"There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations."

This warning highlights the potential risk of stomach contents entering the lungs during surgical procedures, even when patients have followed fasting guidelines.

Mechanism and Effects of GLP-1 Medications

GLP-1 receptor agonists work by:

1. Helping control blood sugar levels in people with diabetes
2. Slowing down the movement of food through the digestive system

These effects contribute to increased feelings of fullness and aid in weight loss. However, the slowed gastric emptying may also increase the risk of residual stomach contents during anesthesia.

Recommendations for Patients and Healthcare Providers

In light of this new warning, the FDA advises:

1. Patients should inform all healthcare providers about their use of GLP-1 medications before any planned surgeries or procedures.
2. Healthcare providers should be aware of this risk and may need to adjust preoperative care plans for patients taking these medications.
3. Some experts suggest stopping weekly GLP-1 medications one week prior to scheduled procedures to minimize risks.

While the risk of pulmonary aspiration is rare, this update emphasizes the importance of careful management for patients on GLP-1 medications undergoing surgical procedures.